English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Anti-alpha4 integrin antibody, natalizumab (Antegren), is a monoclonal antibody to a4b1 integrin adhesion molecules expressed on activated monocytes and CD4 cells. A 1-year followup of 28 patients with relapsing multiple sclerosis, randomized to 3 groups in a double-blind pharmacokinetic study, are presented. One group received placebo, a second group low doses (0.01–0.3 mg/kg) of natalizumab, and a third group high doses (1–3 mg/kg) of natalizumab. The observed reduction of relapses in all natalizumab-treated patients with multiple sclerosis suggests a potential range of doses to induce stabilization of the disease.

Reduction of Relapses in Multiple Sclerosis after Anti-Alpha4 Integrin Antibody (Natalizumab)